A preliminary study suggests that the combination of enfortumab vedotin and pembrolizumab may be a promising option for treating urothelial cancer.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Thomas Flaig, MD, on Novel Combination Therapy for Advanced Urothelial Cancer
Default sub title
minute read
by MedPage Today | November 7, 2022
